Evidence map›Paper›PMID 23793291›Full record

ArticleMolecular pharmacology2013

Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface.

James I Fells, Sue Chin Lee, Yuko Fujiwara, Derek D Norman, Keng Gat Lim, Ryoko Tsukahara, Jianxiong Liu, Renukadevi Patil, Duane D Miller, R Jason Kirby and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Design and Development of Autotaxin Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Structure-Based Discovery of Novel Chemical Classes of Autotaxin Inhibitors.International journal of molecular sciences · 2020
    Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Autotaxin: structure-function and signaling.Journal of lipid research · 2014
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

James I FellsDepartment of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA.
Sue Chin Lee
Yuko Fujiwara
Derek D Norman
Keng Gat Lim
Ryoko Tsukahara
Jianxiong Liu
Renukadevi Patil
Duane D Miller
R Jason Kirby
Sandra Nelson
William Seibel
Ruben Papoian
Abby L Parrill
Daniel L Baker
Robert Bittman
Gabor Tigyi
University of Tennessee Health Science Center · USUniversity of Memphis · USQueens College, CUNY · USUniversity of Cincinnati · US

Funding

Ligand Recognition by Phospholipid Growth Factor ReceptorsR01CA092160 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI TIGYI, GABOR J · 2001 to 2022
$5.9M
NCI NIH HHS CA092160NCI NIH HHS R01 CA092160NIMH NIH HHS N01 MH032004
6 · The paper itself

Abstract

Autotaxin (ATX), a lysophospholipase D, plays an important role in cancer invasion, metastasis, tumor progression, tumorigenesis, neuropathic pain, fibrotic diseases, cholestatic pruritus, lymphocyte homing, and thrombotic diseases by producing the lipid mediator lysophosphatidic acid (LPA). A high-throughput screen of ATX inhibition using the lysophosphatidylcholine-like substrate fluorogenic substrate 3 (FS-3) and ∼10,000 compounds from the University of Cincinnati Drug Discovery Center identified several small-molecule inhibitors with IC₅₀ vales ranging from nanomolar to low micromolar. The pharmacology of the three most potent compounds: 918013 (1; 2,4-dichloro-N-(3-fluorophenyl)-5-(4-morpholinylsulfonyl) benzamide), 931126 (2; 4-oxo-4-{2-[(5-phenoxy-1H-indol-2-yl)carbonyl]hydrazino}-N-(4-phenylbutan-2-yl)butanamide), and 966791 (3; N-(2,6-dimethylphenyl)-2-[N-(2-furylmethyl)(4-(1,2,3,4-tetraazolyl)phenyl)carbonylamino]-2-(4-hydroxy-3-methoxyphenyl) acetamide), were further characterized in enzyme, cellular, and whole animal models. Compounds 1 and 2 were competitive inhibitors of ATX-mediated hydrolysis of the lysophospholipase substrate FS-3. In contrast, compound 3 was a competitive inhibitor of both FS-3 and the phosphodiesterase substrate p-nitrophenyl thymidine 5'-monophosphate. Computational docking and mutagenesis suggested that compounds 1 and 2 target the hydrophobic pocket, thereby blocking access to the active site of ATX. The potencies of compounds 1-3 were comparable to each other in each of the assays. All of these compounds significantly reduced invasion of A2058 human melanoma cells in vitro and the colonization of lung metastases by B16-F10 murine melanoma cells in C57BL/6 mice. The compounds had no agonist or antagonist effects on select LPA or sphingosine 1-phosphate receptors, nor did they inhibit nucleotide pyrophosphatase/phosphodiesterase (NPP) enzymes NPP6 and NPP7. These results identify the molecular surface of the hydrophobic pocket of ATX as a target-binding site for inhibitors of enzymatic activity.

Indexed as

AnimalsAntineoplastic AgentsBenzamidesBenzeneacetamidesCell Line, TumorDrug Screening Assays, AntitumorHigh-Throughput Screening AssaysHumansHydrazinesHydrophobic and Hydrophilic InteractionsIndolesLung NeoplasmsLysophospholipase DMelanoma, ExperimentalMiceMice, Inbred C57BL2,4-dichloro-N-(3-fluorophenyl)-5-(4-morpholinylsulfonyl)benzamide4-oxo-4-(2-((5-phenoxy-1H-indol-2-yl)carbonyl)hydrazino)-N-(4-phenylbutan-2-yl)butanamideAntineoplastic AgentsBenzamidesBenzeneacetamidesHydrazinesIndolesLysophospholipase DN-(2,6-dimethylphenyl)-2-(N-(2-furylmethyl)(4-(1,2,3,4-tetraazolyl)phenyl)carbonylamino)-2-(4-hydroxy-3-methoxyphenyl)acetamidePhosphodiesterase InhibitorsPhosphoric Diester HydrolasesSulfonamidesTetrazoles

Identifiers

PMID23793291
PMCPMC3876816
OpenAlexW2101809518

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.